08:31 AM EDT, 03/17/2026 (MT Newswires) -- Knight Therapeutics ( KHTRF ) Tuesday said it submitted a supplemental application to the Argentine and Mexican health regulatory agencies, to expand the treatment indications for Minjuvi (tafasitamab).

The additional indication for Minjuvi is in combination with lenalidomide and rituximab, to treat adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one prior line of systemic therapy, a statement said.

The company separately announced today that Brazil has approved Minjuvi to be used in combination with rituximab and lenalidomide to treat adult patients with relapsed or refractory FL.

"In past two years we have launched Minjuvi for the treatment of diffuse large B-cell lymphoma in Brazil, Mexico, and Argentina. More recently, Minjuvi received regulatory approval for the treatment of refractory follicular lymphoma in Brazil," said chief executive Samira Sakhia.

"We continue to advance our pipeline with the submissions for Minjuvi in both Argentina and Mexico. More importantly, Minjuvi is more than a single product. With approvals across distinct indications, it effectively represents multiple therapies within one brand, expanding the ways physicians can use Minjuvi to address different patient needs."